Correlation of PU.1 and signal regulatory protein α1 expression in PU.1 transgenic K562 cells

International Journal of Molecular Medicine

Volumn 29, Issue 2, 2012, Pages 319-323

  Iseki, Yuko ^a   Nakahara, Masako ^b   Kubo, Makoto ^b   Obata, Fumiya ^b   Harigae, Hideo ^c   Takahashi, Shinichiro ^a,b  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hematological malignancies; PU.1; Signal regulatory protein 1, extracellular signal regulated kinase

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA1; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; K562 CELLS; PROTO-ONCOGENE PROTEINS; RECEPTORS, IMMUNOLOGIC; TRANS-ACTIVATORS; TRANSGENES;

EID: 84855175942     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.827     Document Type: Article

References (30)

1. Klemsz MJ, McKercher SR, Celada A, Van Beveren C and Maki RA: The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 61: 113-124, 1990.
2. Chen HM, Zhang P, Voso MT, et al.: Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood 85: 2918-2928, 1995.
3. Scott EW, Simon MC, Anastasi J and Singh H: Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265: 1573-1577, 1994.
4. McKercher SR, Torbett BE, Anderson KL, et al.: Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 15: 5647-5658, 1996. (Pubitemid 26385624)
5. Rosenbauer F, Wagner K, Kutok JL, et al.: Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36: 624-630, 2004. (Pubitemid 38715991)
6. Pettersson M, Sundstrom C, Nilsson K and Larsson LG: The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood 86: 2747-2753, 1995.
7. Huh HJ, Chae SL, Lee M, et al.: CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome. Int J Lab Hematol 31: 344-351, 2009.
8. Imoto A, Okada M, Okazaki T, Kitasato H, Harigae H and Takahashi S: Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells. J Biol Chem 285: 10300-10309, 2010.
9. Barclay AN and Brown MH: The SIRP family of receptors and immune regulation. Nat Rev Immunol 6: 457-464, 2006.
10. Seiffert M, Cant C, Chen Z, et al.: Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94: 3633-3643, 1999.
11. Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J and Ullrich A: A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386: 181-186, 1997. (Pubitemid 27131446)
12. Iseki Y, Imoto A, Okazaki T, Harigae H and Takahashi S: Identification of annexin 1 as a PU.1 target gene in leukemia cells. Leuk Res 33: 1658-1663, 2009.
13. Inomata M, Takahashi S, Harigae H, Kameoka J, Kaku M and Sasaki T: Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias. Leuk Res 30: 659-664, 2006.
14. Takahashi S, Harigae H, Ishii KK, et al.: Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. Leuk Res 29: 893-899. 2005. (Pubitemid 40840717)
15. Maekawa T, Imoto A, Satoh T, Okazaki T and Takahashi S: Induction of β-catenin by the suppression of signal regulatory protein α1 in K562 cells. Int J Mol Med 27: 865-872, 2011.
16. Hirosawa M, Nakahara M, Otosaka R, Imoto A, Okazaki T and Takahashi S: The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res 33: 693-699, 2009.
17. Shen SH, Bastien L, Posner BI and Chretien P: A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 352: 736-739, 1991. (Pubitemid 21912421)
18. Yi TL, Cleveland JL and Ihle JN: Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol 12: 836-846, 1992.
19. Zhang Q, Raghunath PN, Vonderheid E, Odum N and Wasik MA: Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157: 1137-1146, 2000.
20. Oka T, Ouchida M, Koyama M, et al.: Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62: 6390-6394, 2002. (Pubitemid 35364092)
21. Chim CS, Fung TK, Cheung WC, Liang R and Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103: 4630-4635, 2004. (Pubitemid 38745995)
22. Wlodarski P, Zhang Q, Liu X, Kasprzycka M, Marzec M and Wasik MA: PU.1 activates transcription of SHP-1 gene in hematopoietic cells. J Biol Chem 282: 6316-6323, 2007. (Pubitemid 47100817)
23. Alldridge LC, Harris HJ, Plevin R, Hannon R and Bryant CE: The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 274: 37620-37628, 1999. (Pubitemid 30026818)
24. Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 4: 36, 2011.
25. Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood 101: 4667-4679, 2003.
26. Milella M, Kornblau SM, Estrov Z, et al.: Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108: 851-859, 2001. (Pubitemid 32880294)
27. Takahashi S: Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells. Am J Hematol 81: 154-155, 2006.
28. Martelli AM, Nyakern M, Tabellini G, et al.: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928, 2006. (Pubitemid 43797279)
29. Takahashi S, McConnell MJ, Harigae H, et al.: The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood 103: 4650-4658, 2004. (Pubitemid 38745998)
30. Takahashi S: Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol 4: 13, 2011.